| 2026-08-18 |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Regulatory VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR ANBENITAMAB (KN026) AND DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER ACCEPTED BY THE NMPA irasia.com ↗
|
| 2026-08-04 |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Regulatory VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR ANBENITAMAB (KN026) AND DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT ACCEPTED BY THE NMPA irasia.com ↗
|
| 2026-07-14 |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Regulatory VOLUNTARY ANNOUNCEMENT - DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) AND ANBENITAMAB (KN026) GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE FIRST-LINE TREATMENT OF ADVANCED HER2-POSITIVE BREAST CANCER irasia.com ↗
DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) AND ANBENITAMAB (KN026) GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE FIRST-LINE TREATMENT OF ADVANCED HER2-POSITIVE BREAST CANCER |
| 2026-06-10 |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Results VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR FIRST-LINE TREATMENT OF HER2-POSITIVE ADVANCED BREAST CANCER MEETS PRIMARY ENDPOINT irasia.com ↗
|
| 2026-06-01 |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Results PHASE III CLINICAL STUDY RESULTS OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER SELECTED FOR LBA ORAL PRESENTATION AT THE 2026 ASCO ANNUAL MEETING irasia.com ↗
Assessed by BIRC, the tpCR rate in the experimental group was 62.4% (95% Confidence Interval (‘‘CI’’): 56.2 –68.2), which was significantly higher than the 51.2% (95% CI: 44.9 –57.4) in the control group (one-sided P=0.0036), showing a statistically significant difference. |
| 2026-03-31 |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Results VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER2+ BREAST CANCER MEETS PRIMARY ENDPOINT irasia.com ↗
|
| 2022-07-28 |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Regulatory VOLUNTARY ANNOUNCEMENT - DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF GASTRIC CANCER irasia.com ↗
DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF GASTRIC CANCER |